Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 43% Improvement Relative Risk HCQ for COVID-19  Ebongue et al.  LATE TREATMENT Is late treatment with HCQ + AZ beneficial for COVID-19? Retrospective 580 patients in Cameroon Lower mortality with HCQ + AZ (p=0.04) Ebongue et al., Travel Medicine and In.., Mar 2022 Favors HCQ Favors control

Factors predicting in-hospital all-cause mortality in COVID 19 patients at the Laquintinie Hospital Douala, Cameroon

Ebongue et al., Travel Medicine and Infectious Disease, doi:10.1016/j.tmaid.2022.102292
Mar 2022  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective 580 hospitalized COVID+ patients in Cameroon, showing lower mortality with HCQ+AZ treatment.
risk of death, 43.0% lower, HR 0.57, p = 0.04, treatment 93 of 522 (17.8%), control 36 of 58 (62.1%), NNT 2.3, adjusted per study, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ebongue et al., 18 Mar 2022, retrospective, Cameroon, peer-reviewed, 27 authors, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
This PaperHCQAll
Factors predicting in-hospital all-cause mortality in COVID 19 patients at the Laquintinie Hospital Douala, Cameroon
Marie Solange Ndom Ebongue, Daniel Lemogoum, Laurent Mireille Endale-Mangamba, Blaise Barche, Christian Eyoum, Styve Hermane Simo Yomi, David Mekolo, Vincent Ngambi, Jacques Doumbe, Christiane Medi Sike, Jerome Boombhi, Grace Ngondi, Christian Biholong, Josephine Kamdem, Liliane Mbenoun, Calixthe Kuaté Tegeu, Armel Djomou, Anastase Dzudie, Felicité Kamdem, Ferdinand Ndom Ntock, Liliane Kuaté Mfeukeu, Eugène Sobngwi, Ida Penda, Richard Njock, Noel Essomba, Jean Cyr Yombi, William Ngatchou
Travel Medicine and Infectious Disease, doi:10.1016/j.tmaid.2022.102292
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Death Crude
Acc, Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19
Albani, Fusina, Giovannini, Ferretti, Granato et al., Impact of Azithromycin or Hydroxychloroquine on Hospital Mortality in COVID-19, Journal of Clinical Medicine, doi:10.3390/jcm9092800
Alghamdi, Barakat, Berrou, Alzahrani, Haseeb et al., Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an J o u r n a l P r e -p r o o f Observational Comparative Study in Saudi Arabia, Antibiotics, doi:10.3390/antibiotics10040365
Bepouka, Izizag; Mandina, Makulo, Robert, None
Boulle, Davies, Husey, Risk factors for COVID-19 death in a population cohort study from the Wester Cape Province, South Africa, Clinical Infectious Diseases, doi:10.1093/cid/ciaa1198
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.105949
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, New England Journal of Medicine, doi:10.1056/nejmoa2012410
Grasselli, Zangrillo, Zanella, COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy, JAMA
Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in hospitalized patients with Covid-19 -preliminary report, N Engl J Med, doi:10.1056/NEJMoa2021436
Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in hospitalized patients with Covid-19 -preliminary report, N Engl J Med, doi:10.1056/NEJMoa2021436
Hullan, COVID-19 and health care inaccessibility in sub-Saharan Africa
J O U R N A L P R E, -p r o o f
J O U R N A L P R E, -p r o o f
Longokolo, Predictors of mortality in COVID-19 patients at Kinshasa University Hospital, Democratic Republic of the Congo (from March to June 2020 ), Pan African Medical Journal
Lozano, Naghavi, Foreman, Lim, Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet
Mancia, Fagard, Narkiewicz, Redon, Zanchetti et al., ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), European Heart Journal, doi:10.1093/eurheartj/eht151
Mikami, Miyashita, Yamada, Harrington, Steinberg et al., Risk factors for mortality in patients with COVID-19 in New York city, Journal of General InternalMedicine
Ncd, Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 191 million participants, Lancet
Quahp, Phua, Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature, Critical care, doi:10.1186/s13054-020-03006-1
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State, JAMA -Journal of the American Medical Association, doi:10.1001/jama.2020.8630
Salyer, Maeda, Sembuche, Kebede, Tshangela et al., The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study, Lancet, doi:10.1016/S0140-6736(21)00632-2
Tartof, Qian, Hong, Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization, Ann Intern Med
Wang, Hu, Hu, Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan
Wu, Chen, Cai, Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China, JAMA Intern Med, doi:10.1001/jamainternmed.2020.0994
Zeberg, Pääbo, The major genetic risk factor for severe COVID-19 is inherited from Neandertals, bioRxiv, doi:10.1101/2020.07.03.186296
Zhang, Bastard, Liu, Pen, Velez, Inborn errors of type I IFN immunity in patients with life-threatening COVID-19, Science, doi:10.1126/science.abd4570
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop